Accessibility Menu
Gemini Therapeutics, Inc. logo

Gemini Therapeutics, Inc.(NASDAQ) GMTX

This security has been delisted. This page is retained for historical reference.

Gemini Therapeutics, Inc. last closing stock price
MetricPriceDate
Last closeUSD 74.652026-07-28
Gemini Therapeutics, Inc. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.23%USD 75.582026-07-21
1 month-0.17%USD 74.782026-06-26
3 month+13.16%USD 65.972026-04-29
Year to date-5.99%USD 79.412025-12-31
1 year+25.5%USD 59.482025-07-28
3 year+54.11%USD 48.442023-07-28
5 year+70.43%USD 43.802021-07-29
Since inception-86.89%USD 103.002020-08-12

GMTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

GMTX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Gemini Therapeutics, Inc. Performance Analysis

Gemini Therapeutics, Inc. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Gemini Therapeutics, Inc. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -45.0510.0%
20232023-12-31USD -3.42-92.4%
20242024-12-31USD -3.9615.7%
20252025-12-31USD -6.0151.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.09

+4.4%

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$15.84

+0.8%

Employees

154

+1.9%

Net Income

-$63.50

+1.9%

EBITDA

-$69.44

+1.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$119.97

+19.1%

Total Debt

$31.06

+1.0%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$30.64

+1.0%

Short Term Debt

$0.42

+0.9%

Return on Assets

-33.11%

+1.5%

Return on Invested Capital

-28.92%

-1.2%

Free Cash Flow

-$62.24

+1.5%

Operating Cash Flow

-$62.24

+1.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANPCAnPac Bio-Medical Science Co., Ltd.
$4.30-3.15%
LMNLLiminal BioSciences Inc.
$8.50+0.12%
FRLNFreeline Therapeutics Holdings plc
$6.49+0.15%
VINCVincerx Pharma, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.41-0.06%
TAT&T
$23.94-0.03%
SMRNuScale Power
$7.59-0.08%
ORCLOracle
$117.74-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.